| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3848 |
| Trial ID | NCT06364423 |
| Disease | B-Cell Chronic Lymphocytic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Rituximab |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) |
| Year | 2024 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 10001599|001599-C |
| Cohort 1 | |||||||||||
|
|||||||||||